[{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"LongRiver Investments","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Large molecule","year":"2024","type":"Series A Financing","leadProduct":"RN0191","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Rona Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Rona Therapeutics \/ LongRiver Investments","highestDevelopmentStatusID":"6","companyTruncated":"Rona Therapeutics \/ LongRiver Investments"},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Oligonucleotide","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Rona Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rona Therapeutics \/ Lilly Asia Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Rona Therapeutics \/ Lilly Asia Ventures"},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Rona Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rona Therapeutics \/ Rona Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Rona Therapeutics \/ Rona Therapeutics"},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"RN0361","moa":"APOC3 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Rona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rona Therapeutics \/ Inapplicable"}]